Celgene has paid US$225 M upfront to expand its relationship with Forma Therapeutics with a multistage drug discovery collaboration covering a broad range of protein target families and therapeutic areas. The new deal will have an initial term of 3.5 years and could last for more than 7 years if Celgene elects to exercise options to enter into two additional collaborations. If it chooses to do so, Celgene will have an exclusive option to buy Forma during the third collaboration term. The two companies first partnered in April 2013 to discover and develop drugs targeting protein homeostasis.